Activation of Peroxisome Proliferator-Activated Receptor γ Suppresses Telomerase Activity in Vascular Smooth Muscle Cells
Authors:
- 14 April 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 98 (7) , e50-9
Abstract
Activation of the peroxisome proliferator-activated receptor (PPAR) γ, the molecular target for insulin sensitizing thiazolidinediones used in patients with type 2 diabetes, inhibits vascular smooth muscle cell (VSMC) proliferation and prevents atherosclerosis and neointima formation. Emerging evidence indicates that telomerase controls key cellular functions including replicative lifespan, differentiation, and cell proliferation. In the present study, we demonstrate that ligand-induced and constitutive PPARγ activation inhibits telomerase activity in VSMCs. Telomerase reverse transcriptase (TERT) confers the catalytic activity of telomerase, and PPARγ ligands inhibit TERT expression through a receptor-dependent suppression of the TERT promoter. 5′-deletion analysis, site-directed mutagenesis, and transactivation studies using overexpression of Ets-1 revealed that suppression of TERT transcription by PPARγ is mediated through negative cross-talk with Ets-1–dependent transactivation of the TERT promoter. Chromatin immunoprecipitation assays further demonstrated that PPARγ ligands inhibit Ets-1 binding to the TERT promoter, which is mediated at least in part through an inhibition of Ets-1 expression by PPARγ ligands. In VSMCs overexpressing TERT, the efficacy of PPARγ ligands to inhibit cell proliferation is lost, indicating that TERT constitutes an important molecular target for the antiproliferative effects of PPARγ ligands. Finally, we demonstrate that telomerase activation during the proliferative response after vascular injury is effectively inhibited by PPARγ ligands. These findings provide a previously unrecognized mechanism for the antiproliferative effects of PPARγ ligands and support the concept that PPARγ ligands may constitute a novel therapeutic approach for the treatment of proliferative cardiovascular diseases.Keywords
This publication has 50 references indexed in Scilit:
- PPAR-γ inhibits ANG II-induced cell growth via SHIP2 and 4E-BP1American Journal of Physiology-Heart and Circulatory Physiology, 2006
- Pioglitazone Reduces Neointima Volume After Coronary Stent ImplantationCirculation, 2005
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialThe Lancet, 2005
- Peroxisome Proliferator-Activated Receptors and AtherogenesisCirculation Research, 2004
- Peroxisome Proliferator-Activated Receptor γ: Implications for Cardiovascular DiseaseHypertension, 2004
- Inhibitory Activity of Clinical Thiazolidinedione Peroxisome Proliferator Activating Receptor-γ Ligands Toward Internal Mammary Artery, Radial Artery, and Saphenous Vein Smooth Muscle Cell ProliferationCirculation, 2003
- Human telomerase accelerates growth of lens epithelial cells through regulation of the genes mediating RB/E2F pathwayOncogene, 2002
- PPAR activators inhibit endothelial cell migration by targeting AktBiochemical and Biophysical Research Communications, 2002
- Peroxisome Proliferator–Activated Receptor-γ Ligands Inhibit Nuclear but Not Cytosolic Extracellular Signal–Regulated Kinase/Mitogen–Activated Protein Kinase–Regulated Steps in Vascular Smooth Muscle Cell MigrationJournal of Cardiovascular Pharmacology, 2001
- PPARγ and the Treatment of Insulin ResistanceTrends in Endocrinology & Metabolism, 2000